Sachin Yende1, Shamly Austin, Andrew Rhodes, Simon Finfer, Steven Opal, Taylor Thompson, Fernando A Bozza, Steven P LaRosa, V Marco Ranieri, Derek C Angus. 1. 1The Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA. 2Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA. 3Research and Development, Quality Improvement Department, Gateway Health, Pittsburgh, PA. 4Adult Critical Care, St. George's University Hospitals, NHS Foundation Trust, London, United Kingdom. 5The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia. 6Infectious Disease Division, Alpert Medical School of Brown University, Pawtucket, RI. 7Pulmonary and Critical Care Division, Massachusetts General Hospital, Boston, MA. 8Evandro Chagas National Institute of Infectious Diseases, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil. 9Beverly Hospital, Lahey Health System, Beverly, MA. 10Department of Anesthesia and Intensive Care Medicine, University Sapienza of Rome, Policlino Umberto I Hospital, Rome, Italy.
Abstract
OBJECTIVES: To describe the quality of life among sepsis survivors. DESIGN: Secondary analyses of two international, randomized clinical trials (A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis [derivation cohort] and PROWESS-SHOCK [validation cohort]). SETTING: ICUs in North and South America, Europe, Africa, Asia, and Australia. PATIENTS: Adults with severe sepsis. We analyzed only patients who were functional and living at home without help before sepsis hospitalization (n = 1,143 and 987 from A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, respectively). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: In A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, the average age of patients living at home independently was 63 and 61 years; 400 (34.9%) and 298 (30.2%) died by 6 months. In A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis, 580 patients had a quality of life measured using EQ-5D at 6 months. Of these, 41.6% could not live independently (22.7% were home but required help, 5.1% were in nursing home or rehabilitation facilities, and 5.3% were in acute care hospitals). Poor quality of life at 6 months, as evidenced by problems in mobility, usual activities, and self-care domains were reported in 37.4%, 43.7%, and 20.5%, respectively, and the high incidence of poor quality of life was also seen in patients in PROWESS-SHOCK. Over 45% of patients with mobility and self-care problems at 6 months in A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis died or reported persistent problems at 1 year. CONCLUSIONS: Among individuals enrolled in a clinical trial who lived independently prior to severe sepsis, one third had died and of those who survived, a further one third had not returned to independent living by 6 months. Both mortality and quality of life should be considered when designing new interventions and considering endpoints for sepsis trials.
RCT Entities:
OBJECTIVES: To describe the quality of life among sepsis survivors. DESIGN: Secondary analyses of two international, randomized clinical trials (A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis [derivation cohort] and PROWESS-SHOCK [validation cohort]). SETTING: ICUs in North and South America, Europe, Africa, Asia, and Australia. PATIENTS: Adults with severe sepsis. We analyzed only patients who were functional and living at home without help before sepsis hospitalization (n = 1,143 and 987 from A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, respectively). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: In A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, the average age of patients living at home independently was 63 and 61 years; 400 (34.9%) and 298 (30.2%) died by 6 months. In A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis, 580 patients had a quality of life measured using EQ-5D at 6 months. Of these, 41.6% could not live independently (22.7% were home but required help, 5.1% were in nursing home or rehabilitation facilities, and 5.3% were in acute care hospitals). Poor quality of life at 6 months, as evidenced by problems in mobility, usual activities, and self-care domains were reported in 37.4%, 43.7%, and 20.5%, respectively, and the high incidence of poor quality of life was also seen in patients in PROWESS-SHOCK. Over 45% of patients with mobility and self-care problems at 6 months in A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis died or reported persistent problems at 1 year. CONCLUSIONS: Among individuals enrolled in a clinical trial who lived independently prior to severe sepsis, one third had died and of those who survived, a further one third had not returned to independent living by 6 months. Both mortality and quality of life should be considered when designing new interventions and considering endpoints for sepsis trials.
Authors: V Marco Ranieri; B Taylor Thompson; Philip S Barie; Jean-François Dhainaut; Ivor S Douglas; Simon Finfer; Bengt Gårdlund; John C Marshall; Andrew Rhodes; Antonio Artigas; Didier Payen; Jyrki Tenhunen; Hussein R Al-Khalidi; Vivian Thompson; Jonathan Janes; William L Macias; Burkhard Vangerow; Mark D Williams Journal: N Engl J Med Date: 2012-05-22 Impact factor: 91.245
Authors: Bradford D Winters; Michael Eberlein; Janice Leung; Dale M Needham; Peter J Pronovost; Jonathan E Sevransky Journal: Crit Care Med Date: 2010-05 Impact factor: 7.598
Authors: Faraaz Ali Shah; Francis Pike; Karina Alvarez; Derek Angus; Anne B Newman; Oscar Lopez; Judith Tate; Vishesh Kapur; Anthony Wilsdon; Jerry A Krishnan; Nadia Hansel; David Au; Mark Avdalovic; Vincent S Fan; R Graham Barr; Sachin Yende Journal: Am J Respir Crit Care Med Date: 2013-09-01 Impact factor: 21.405
Authors: Steven M Opal; Pierre-Francois Laterre; Bruno Francois; Steven P LaRosa; Derek C Angus; Jean-Paul Mira; Xavier Wittebole; Thierry Dugernier; Dominique Perrotin; Mark Tidswell; Luis Jauregui; Kenneth Krell; Jan Pachl; Takeshi Takahashi; Claus Peckelsen; Edward Cordasco; Chia-Sheng Chang; Sandra Oeyen; Naoki Aikawa; Tatsuya Maruyama; Roland Schein; Andre C Kalil; Marc Van Nuffelen; Melvyn Lynn; Daniel P Rossignol; Jogadish Gogate; Mary B Roberts; Janice L Wheeler; Jean-Louis Vincent Journal: JAMA Date: 2013-03-20 Impact factor: 56.272
Authors: Kelly Thompson; Colman Taylor; Stephen Jan; Qiang Li; Naomi Hammond; John Myburgh; Manoj Saxena; Balasubramanian Venkatesh; Simon Finfer Journal: Intensive Care Med Date: 2018-06-27 Impact factor: 17.440
Authors: Juciano Gasparotto; Carolina S Girardi; Nauana Somensi; Camila T Ribeiro; José C F Moreira; Monique Michels; Beatriz Sonai; Mariane Rocha; Amanda V Steckert; Tatiana Barichello; João Quevedo; Felipe Dal-Pizzol; Daniel P Gelain Journal: J Biol Chem Date: 2017-11-10 Impact factor: 5.157
Authors: Heather A King; Sarah B Doernberg; Julie Miller; Kiran Grover; Megan Oakes; Felicia Ruffin; Sarah Gonzales; Abigail Rader; Michael J Neuss; Hayden B Bosworth; Zoë Sund; Caitlin Drennan; Jonathan M Hill-Rorie; Pratik Shah; Laura Winn; Vance G Fowler; Thomas L Holland Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079